Crizotinib
Other name
DB08865
International/Other brands
Xalkori
Groups
Approved
Structure
Prescription products
| Name | Dosage | Strength | Route | Labeller |
|---|---|---|---|---|
| Xalkori | Capsule | 200 mg | Oral | Pfizer |
| Xalkori | Capsule | 250 mg | Oral | Pfizer |
| Xalkori | Capsule | 200 mg/1 | Oral | Pfizer Laboratories Div Pfizer Inc. |
| Xalkori | Capsule | 250 mg/1 | Oral | Pfizer Laboratories Div Pfizer Inc. |
Target
-
Description
Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications
Metastatic Non-Small Cell Lung Cancer
Other indications
-
Mechaism of action
-
Absorption
The peak serum concentration was reached in 4 to 6 hours following an oral single-dose administration. Steady state was reached within 15 days when a dose of 250 mg twice daily was administered. The mean absolute bioavailability was 43% (range of 32% to 66%) following a single 250 mg oral dose. When taken with high-fat meal, AUC and Cmax were reduced.
Metabolism
Crizotinib is metabolized by CYP3A4 and CYP3A5 in which these enzymes mediates the O-dealkylation of the drug.
Toxicity
-